We are willing to litigate our CRISPR patents, says IP chief on the CVC side
ERS Genomics’ Michael Arciero shares his views on the Cas9 licensing landscape in an exclusive IAM interview
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.